{"result": "(\"entity\"<|>MEN1<|>EVENT<|>MEN1 is a syndrome characterized by multiple endocrine neoplasia, which includes various tumors and hormonal imbalances, often requiring genetic study and clinical management.)\n##\n(\"entity\"<|>ENETS<|>ORGANIZATION<|>ENETS, or the European Neuroendocrine Tumor Society, is an organization that provides guidelines and support for the treatment of neuroendocrine tumors in Europe.)\n##\n(\"entity\"<|>NANETS<|>ORGANIZATION<|>NANETS, or the North American Neuroendocrine Tumor Society, is an organization focused on the research and treatment of neuroendocrine tumors in North America.)\n##\n(\"entity\"<|>PHILADELPHIA<|>GEO<|>Philadelphia is a city in the United States where the Williams Textbook of Endocrinology was published, providing important medical guidelines.)\n##\n(\"entity\"<|>SOCIETY ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Sociedad Española de Endocrinología y Nutrición is a Spanish society that focuses on endocrinology and nutrition, providing resources and guidelines for practitioners.)\n##\n(\"entity\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>EVENT<|>The Williams Textbook of Endocrinology is a comprehensive medical textbook that covers various aspects of endocrinology, including guidelines for managing conditions like MEN1.)\n##\n(\"entity\"<|>VALDÉS GALLEGO N.<|>PERSON<|>Valdés Gallego N. is an author associated with the Manual de Endocrinología y Nutrición, which discusses endocrine neoplasia and related topics.)\n##\n(\"relationship\"<|>MEN1<|>ENETS<|>ENETS provides clinical practice guidelines for the management of MEN1 syndrome<|>8)\n##\n(\"relationship\"<|>MEN1<|>NANETS<|>NANETS offers guidelines and support for the treatment of MEN1 in North America<|>8)\n##\n(\"relationship\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>ENETS<|>The Williams Textbook of Endocrinology is referenced by ENETS for clinical guidelines<|>6)\n##\n(\"relationship\"<|>WILLIAMS TEXTBOOK OF ENDOCRINOLOGY<|>NANETS<|>The Williams Textbook of Endocrinology is referenced by NANETS for clinical guidelines<|>6)\n##\n(\"relationship\"<|>VALDÉS GALLEGO N.<|>SOCIETY ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Valdés Gallego N. is associated with the Sociedad Española de Endocrinología y Nutrición, contributing to the field of endocrinology<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: : de las células paratiroides (90-100%),                                    en MEN1. Su prevalencia (37-75%) ha aumentado en los últimos años por la mayor sensibili-\n         de las células endocrinas pancreatoduodenales (30-70%)                      y/o de las    células hipofisarias            dad de los estudios de imagen, sobre todo la prevalencia de los TNE pancreáticos no funcio-\n         (10-65%). Ante este diagnóstico existe indicación de realizar el estudio del gen MEN1 para                                nantes que se consideran actualmente los tumores pancreáticos más frecuentes en MEN1.\n         confirmar el diagnóstico y poder estudiar a los familiares.                                                               Los TNE pancreáticos          no funcionantes        no están asociados a         ningún    síndrome clínico\n         El adenoma secretor de PRL es el más común de los tumores hipofisarios en MEN1. En la                                     porque habitualmente no secretan ninguna hormona, un tercio de ellos ni siquiera cromo-\n         serie franco-belga publicada en 2002, los pacientes con MEN1 tenían tres veces más pro-                                   granina A; en otras ocasiones, se detectan niveles elevados de polipéptido pancreático o\n         babilidades de tener un macroadenoma que un microadenoma hipofisario, aunque recien-                                      glucagón que no producen ningún síntoma.\n         temente los datos de la serie neerlandesa no corroboraron estos hallazgos quizás porque                                   Estos tumores pueden malignizar en aproximadamente el 30% de los pacientes, por lo que\n         más pacientes fueron diagnosticados tras cribado genético.                                                                dada su frecuencia (40-80%) son la principal causa de mortalidad en los pacientes MEN1\n         Los síntomas clínicos y el tratamiento es igual que en los casos esporádicos, aunque se ha                                en la actualidad. Se han descrito en pacientes de 12 años; por ello, la Guía Clínica de 2012\n         descrito que suelen ser más resistentes al tratamiento médico y tienen mayor tendencia a                                  recomienda realizar estudios de imagen abdominales a partir de los 10 años.\n         recurrir tras la cirugía, aunque nuevamente la serie neerlandesa no confirma estos datos.                                 Tratamiento: existe controversia sobre el momento del tratamiento quirúrgico en pacientes\n         En esta paciente se debería haber sospechado el síndrome de MEN1 ante la persistencia                                     asintomáticos. La Guía Clínica de 2012 recomienda la intervención quirúrgica si el tumor\n         del HPP tras la cirugía, unido a la presencia de dos adenomas y a la edad de diagnóstico                                  es mayor de 1 cm, sobre todo si ha presentado crecimiento en los últimos 6 meses. Por\n\n\n\n410                                                                                                                                                                                                                                                     411\n---\n                                                                                                                                                                                 METABOLISMO FOSFOCÁLCICO, TUMORES                                        7\n                                                                                                                                                                                                                NEUROENDOCRINOS Y MEN\n\n\n\n         el contrario, en los últimos años se han publicado series retrospectivas de pacientes con                                                   Casos clínicos. Caso clínico 2\n         síndrome MEN1 que apoyan la actitud más conservadora de intervención quirúrgica solo\n         si los tumores son de 2 cm o más. Esta recomendación está avalada por la sociedad eu-\n         ropea (ENETS, Eurpoean Neuroendocrine Tumor Society) y la norteamericana de tumores                                                           44     ¿Cuál de las siguientes repuestas es verdadera?\n         neuroendocrinos (NANETS, North American Neuroendocrine Tumor Society) y los grupos\n         francés y holandés de neoplasia endocrina múltiple tipo 1.                                                                                           A. El pH gástrico de esta paciente probablemente será alcalino.\n         Referencias:                                                                                                                                         B. El pH gástrico de esta paciente probablemente será ácido.\n         • Melmed S, Polonsky KS, Reed Larsen P, Kronenberg HM. Williams Textbook of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016.                    C. La concentración de gastrina estará elevada.\n         • Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, et al. Clinical Practice Guidelines for Multiple Endocrine Neoplasia\n           Type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:1-22.\n         • Valdés Gallego N. Manual de Endocrinología y Nutrición (Internet). Capítulo 3. Neoplasia Endocrina Múltiple. Madrid: Sociedad                      D.   B y C son ciertas.\n           Española de Endocrinología y Nutrición; 2015. Disponible en: https://manual.seen.es.\n\n\n\n                                                                                                                                                       45     En el caso de que los resultados de la determinación basal de hormonas\n         En el caso anterior, hemos de seguir a esta paciente con vigilancia mediante                                                                         gastrointestinales no fueran concluyentes, ¿qué prueba funcional resultaría útil?\n     43  cribado periódico bioquímico y/o morfológico para detect\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}